Previous 10 | Next 10 |
Immatics press release ( NASDAQ: IMTX ): Q2 GAAP EPS of -€0.22 Collaboration Revenue of €17.21M (+231.6% Y/Y) Cash and cash equivalents as well as other financial assets total €324.4 million ($337.0 million) as of June 30, 2022, compared to ...
ACTengine ® TCR-T cell therapy targeting PRAME is enrolling patients in all three P hase 1b cohorts : IMA203 monotherapy at provisional recommended Phase 2 dose (RP2D) (Cohort A) , IMA203/ nivolumab che...
Improving VBR pick performance since late July is discussed. 5 new buy signals are highlighted. A super-bullish technical and fundamental setup for Canadian Solar is analyzed in more detail. During the last few weeks, I have been able to find some decent winners for Seek...
A performance review explains strong relative gains this past week for initial picks. 5 new buy signals are discussed. Reading International -Class A- shares are highlighted and analyzed in more detail. We finally have some big winners over the last week to discuss from ...
Quick review of past picks and my selection process. Explanation of how missing one big winner can dramatically alter performance totals. 4 new VBR buy signals outlined. "Volume precedes price" is an idea with some statistical backing, widely followed by traders and inve...
Cancer immunotherapy developer Immatics ( NASDAQ: IMTX ) is up 17% in Tuesday afternoon trading on volume that is ( IMTX ) four times higher than the normal daily average. Average volume for the stock is 146,757. As of 230p ET, ~586K shares had traded hands. Th...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
Gene editing company Editas Medicine (NASDAQ:EDIT) and German biotech Immatics N.V. (IMTX) announced a research collaboration and licensing agreement on Tuesday to develop treatments for cancer. The deal combines Editas’ (EDIT) gene-editing technology with Immatics’ (IMTX) ACTal...
Immatics N.V. ( NASDAQ:IMTX ) is currently valued at $7.55. The stock has been bullish over the last three weeks. In that period, it emerged from the bottom at $6.60 and the lowest price of $5.75. Our analysis shows that the stock carries a lot of potential for patient investors. ...
Immatics press release (NASDAQ:IMTX): Q1 GAAP EPS of €$1.35. Revenue of €102.91M (+1290.7% Y/Y). Shares up 16% PM. Cash and cash equivalents as well as other financial assets of $280.5M (€252.7M) as of March 31, 2022. With the upfront payment from...
News, Short Squeeze, Breakout and More Instantly...
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-conc...
2024-07-12 10:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...